IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(1.22) per share which missed the analyst consensus estimate of $(1.09) by 11.93 percent. This is a 38.64 percent decrease over losses of $(0.88) per share from the same period last year. The company reported quarterly sales of $8.857 million which beat the analyst consensus estimate of $5.015 million by 76.60 percent.